University of Pennsylvania-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2024

  1. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 6, pp. 1279-1292

2023

  1. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

2021

  1. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Complementing the cancer-immunity cycle

    Frontiers in Immunology, Vol. 10, Núm. APR

  3. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2018

  1. An instrument for studying granular media in low-gravity environment

    Review of Scientific Instruments, Vol. 89, Núm. 7

2017

  1. T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions

    Cell Reports, Vol. 18, Núm. 4, pp. 857-865

2014

  1. T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy

    Cancer Discovery, Vol. 4, Núm. 5, pp. 522-526

  2. The role of complement in tumor growth

    Advances in Experimental Medicine and Biology

2013

  1. Complement inhibition in cancer therapy

    Seminars in Immunology, Vol. 25, Núm. 1, pp. 54-64

2012

  1. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

    Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683